New Zealand markets open in 5 hours 6 minutes

PODD Dec 2024 220.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
63.700.00 (0.00%)
As of 03:21PM EDT. Market open.
Full screen
Previous close63.70
Open63.16
Bid31.40
Ask34.50
Strike220.00
Expiry date2024-12-20
Day's range62.64 - 63.70
Contract rangeN/A
Volume181
Open interest100
  • Bloomberg

    Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks

    (Bloomberg) -- The new class of weight-loss drugs are being tested as cure-alls for everything from knee replacements to liver disease and throwing corners of the stock market into disarray.Most Read from BloombergHow Long Can High Rates Last? Bond Markets Say Maybe ForeverJain Raises $5.3 Billion in Biggest Hedge Fund Debut Since 2018Nvidia Sales Grow So Fast That Wall Street Can’t Keep UpBuzzFeed Struggles to Sell Owner of Hit YouTube Show ‘Hot Ones’Volatility Grips Stocks as Nvidia Rout Accel

  • Zacks

    Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

    Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.

  • Business Wire

    Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

    ACTON, Mass., June 21, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. This landmark study evaluated the impact of AID in a diverse group of people with type 2 diabetes who req